Pfizer reports Elrexfio progression-free survival estimates
Over 75% of Elrexfio patients were progression-free; estimated progression-free survival was 68% at 18 months.
Related stories
Cadiz Raises $21 Million in Registered Direct Offering
Cadiz said it entered into a placement agreement for a registered direct offering. Proceeds are intended to advance development of the Mojave Groundwater Bank.
M impact | EQUITY | Oct 29, 2026, 12:21 PM UTC
Boliden Q3 Revenue Beats on Record Kevitsa Milled Volume
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
Microsoft Reportedly Plans U.S. Bond Issuance
Reuters reports, citing Bloomberg News and people familiar with the matter, that Microsoft plans to issue bonds in the United States.
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
Mastercard Beats Q3 Revenue and Adjusted EPS Estimates
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
West Pharma Executive Says Q3 Cyber-Deferred Revenue Fully Recovered
A West Pharma executive said revenue deferred by a cyber incident in Q3 was fully recovered.
M impact | EQUITY | Oct 29, 2026, 12:17 PM UTC
Microsoft to Raise $25 Billion in U.S. Bond Sale, Bloomberg Reports
Bloomberg News reports that Microsoft plans to raise $25 billion through a U.S. bond sale.
M impact | EQUITY | Oct 29, 2026, 12:17 PM UTC